A deal's first quarter is mostly costs: the Theravance example

Zymeworks' third-quarter 2026 earnings release says the acquisition of Theravance Biopharma closed on September 23. Because that left only seven days in the quarter, the acquisition contributed about $1.5 million of revenue.

The release says the main earnings effect was integration and transaction-related cost. Transaction costs were $3.9 million for the quarter. Severance tied to the deal was $9.0 million. Stock-based compensation included $10.6 million for settling Theravance equity awards attributable to the period after the combination. Selling, general and administrative expense rose to $42.7 million from $14.1 million, mainly because of those items.

On the plus side, the company expects $13 million to $15 million in annualized overhead and corporate cost savings. It describes the deal as adding a recurring commercial cash-flow stream through the product YUPELRI, whose US net sales were $71.5 million in the quarter, up 0.2% from a year earlier. The release says the deal was financed through non-recourse notes totaling $600 million and does not state a purchase price.

Zymeworks also reported net income of $173.7 million for the quarter, which it attributes mainly to a $250.0 million milestone from Jazz, partly offset by the acquisition costs. That is a reminder of how one-time items can swamp the picture in either direction.